A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Jin, Yangbing, Zhang, Zehui, Zou, Siyi, Li, Fanlu, Chen, Hao, Peng, Chenghong, Deng, Xiaxing, Wen, Chenlei, Shen, Baiyong, Zhan, Qian
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010262/
https://ncbi.nlm.nih.gov/pubmed/33816276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.634881
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky